Review





Similar Products

96
InvivoGen odn 2006
Odn 2006, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/odn 2006/product/InvivoGen
Average 96 stars, based on 1 article reviews
odn 2006 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

86
Sangon Biotech cpg odn 2006
Cpg Odn 2006, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpg odn 2006/product/Sangon Biotech
Average 86 stars, based on 1 article reviews
cpg odn 2006 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

96
InvivoGen class b cpg oligodeoxynucleotide odn 2006
Class B Cpg Oligodeoxynucleotide Odn 2006, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/class b cpg oligodeoxynucleotide odn 2006/product/InvivoGen
Average 96 stars, based on 1 article reviews
class b cpg oligodeoxynucleotide odn 2006 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
InvivoGen cpg2006 oligonucleotides
Cpg2006 Oligonucleotides, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpg2006 oligonucleotides/product/InvivoGen
Average 96 stars, based on 1 article reviews
cpg2006 oligonucleotides - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
InvivoGen cpg odn 2006
Cpg Odn 2006, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpg odn 2006/product/InvivoGen
Average 96 stars, based on 1 article reviews
cpg odn 2006 - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
InvivoGen bm ascs
A) Experimental diagram. B) wnnUMAPs of <t>ASCs</t> colored by tissue (left) or subset (right). Data from HD matched fixed CITEseq. C) Percent subset of total ASCs by sample. Data from HD matched fixed CITEseq. D) Percent subisotype usage by sample. Data from HD matched fixed CITEseq. E) Experimental diagram. F) Representative region of interest from a bone marrow core colored by fluorescence signal (top) or subset labels of segmented cells (bottom). Data from HD BM spatial proteomics. G) <t>Percent</t> <t>ASC</t> subset of total cells by individual. Data from HD BM spatial proteomics. H) Computational diagram. I) Observed (black diamond) and randomly permuted (grey density) percent of ASCs found in homotypic niches (defined as all ASCs in a niche having identical subset identities), by individual. Empirical p-values calculated as the number of permutations with homotypic niche frequencies greater or equal to the observed homotypic niche frequency, divided by the number of permutations plus one. Data from HD BM spatial proteomics. J) Computational diagram. K) Scaled enrichment scores of cell types (x-axis) in ASC subset (y-axis) niches by individual (panel). Q-values<0.1 were colored white. Data from HD BM spatial proteomics. L) Representative images (panels) of ASC-rich regions colored by fluorescence signal (left) or cell type labels of segmented cells (right). Data from HD BM spatial proteomics.
Bm Ascs, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bm ascs/product/InvivoGen
Average 96 stars, based on 1 article reviews
bm ascs - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
InvivoGen adjuvants
A) Experimental diagram. B) wnnUMAPs of <t>ASCs</t> colored by tissue (left) or subset (right). Data from HD matched fixed CITEseq. C) Percent subset of total ASCs by sample. Data from HD matched fixed CITEseq. D) Percent subisotype usage by sample. Data from HD matched fixed CITEseq. E) Experimental diagram. F) Representative region of interest from a bone marrow core colored by fluorescence signal (top) or subset labels of segmented cells (bottom). Data from HD BM spatial proteomics. G) <t>Percent</t> <t>ASC</t> subset of total cells by individual. Data from HD BM spatial proteomics. H) Computational diagram. I) Observed (black diamond) and randomly permuted (grey density) percent of ASCs found in homotypic niches (defined as all ASCs in a niche having identical subset identities), by individual. Empirical p-values calculated as the number of permutations with homotypic niche frequencies greater or equal to the observed homotypic niche frequency, divided by the number of permutations plus one. Data from HD BM spatial proteomics. J) Computational diagram. K) Scaled enrichment scores of cell types (x-axis) in ASC subset (y-axis) niches by individual (panel). Q-values<0.1 were colored white. Data from HD BM spatial proteomics. L) Representative images (panels) of ASC-rich regions colored by fluorescence signal (left) or cell type labels of segmented cells (right). Data from HD BM spatial proteomics.
Adjuvants, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adjuvants/product/InvivoGen
Average 96 stars, based on 1 article reviews
adjuvants - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
InvivoGen cpg
A) Experimental diagram. B) wnnUMAPs of <t>ASCs</t> colored by tissue (left) or subset (right). Data from HD matched fixed CITEseq. C) Percent subset of total ASCs by sample. Data from HD matched fixed CITEseq. D) Percent subisotype usage by sample. Data from HD matched fixed CITEseq. E) Experimental diagram. F) Representative region of interest from a bone marrow core colored by fluorescence signal (top) or subset labels of segmented cells (bottom). Data from HD BM spatial proteomics. G) <t>Percent</t> <t>ASC</t> subset of total cells by individual. Data from HD BM spatial proteomics. H) Computational diagram. I) Observed (black diamond) and randomly permuted (grey density) percent of ASCs found in homotypic niches (defined as all ASCs in a niche having identical subset identities), by individual. Empirical p-values calculated as the number of permutations with homotypic niche frequencies greater or equal to the observed homotypic niche frequency, divided by the number of permutations plus one. Data from HD BM spatial proteomics. J) Computational diagram. K) Scaled enrichment scores of cell types (x-axis) in ASC subset (y-axis) niches by individual (panel). Q-values<0.1 were colored white. Data from HD BM spatial proteomics. L) Representative images (panels) of ASC-rich regions colored by fluorescence signal (left) or cell type labels of segmented cells (right). Data from HD BM spatial proteomics.
Cpg, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cpg/product/InvivoGen
Average 96 stars, based on 1 article reviews
cpg - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

Image Search Results


A) Experimental diagram. B) wnnUMAPs of ASCs colored by tissue (left) or subset (right). Data from HD matched fixed CITEseq. C) Percent subset of total ASCs by sample. Data from HD matched fixed CITEseq. D) Percent subisotype usage by sample. Data from HD matched fixed CITEseq. E) Experimental diagram. F) Representative region of interest from a bone marrow core colored by fluorescence signal (top) or subset labels of segmented cells (bottom). Data from HD BM spatial proteomics. G) Percent ASC subset of total cells by individual. Data from HD BM spatial proteomics. H) Computational diagram. I) Observed (black diamond) and randomly permuted (grey density) percent of ASCs found in homotypic niches (defined as all ASCs in a niche having identical subset identities), by individual. Empirical p-values calculated as the number of permutations with homotypic niche frequencies greater or equal to the observed homotypic niche frequency, divided by the number of permutations plus one. Data from HD BM spatial proteomics. J) Computational diagram. K) Scaled enrichment scores of cell types (x-axis) in ASC subset (y-axis) niches by individual (panel). Q-values<0.1 were colored white. Data from HD BM spatial proteomics. L) Representative images (panels) of ASC-rich regions colored by fluorescence signal (left) or cell type labels of segmented cells (right). Data from HD BM spatial proteomics.

Journal: bioRxiv

Article Title: Multi-omic profiling of human antibody-secreting cells reveals diverse subsets sustain durable humoral immunity

doi: 10.64898/2026.04.13.717827

Figure Lengend Snippet: A) Experimental diagram. B) wnnUMAPs of ASCs colored by tissue (left) or subset (right). Data from HD matched fixed CITEseq. C) Percent subset of total ASCs by sample. Data from HD matched fixed CITEseq. D) Percent subisotype usage by sample. Data from HD matched fixed CITEseq. E) Experimental diagram. F) Representative region of interest from a bone marrow core colored by fluorescence signal (top) or subset labels of segmented cells (bottom). Data from HD BM spatial proteomics. G) Percent ASC subset of total cells by individual. Data from HD BM spatial proteomics. H) Computational diagram. I) Observed (black diamond) and randomly permuted (grey density) percent of ASCs found in homotypic niches (defined as all ASCs in a niche having identical subset identities), by individual. Empirical p-values calculated as the number of permutations with homotypic niche frequencies greater or equal to the observed homotypic niche frequency, divided by the number of permutations plus one. Data from HD BM spatial proteomics. J) Computational diagram. K) Scaled enrichment scores of cell types (x-axis) in ASC subset (y-axis) niches by individual (panel). Q-values<0.1 were colored white. Data from HD BM spatial proteomics. L) Representative images (panels) of ASC-rich regions colored by fluorescence signal (left) or cell type labels of segmented cells (right). Data from HD BM spatial proteomics.

Article Snippet: For the ASC culture condition screen, total BM ASCs were stimulated for 72 hours with CpG ODN 2006 (10μg/mL, Invivogen) or BCR crosslinker (anti-kappa light chain; 1μg/mL, Southern Biotech) with various combinations of stimulatory reagents, including MEGACD40L (0.1μg/ml, Enzo Life Sciences), BAFF (1μg/mL, PeproTech), CXCL12 (0.1μg/ml, R&D Systems), IL-2 (0.1μg/mL, Biolegend), and IL-21 (0.1μg/mL, PeproTech).

Techniques: Fluorescence, Spatial Proteomics

A) Experimental diagram. B) Serum Ig concentrations of patients with NDMM by timepoint (x-axis), isotype (y-axis), and the isotype of each patient’s malignant cell (shapes). Transparency indicates values outside the healthy reference ranges specified in the clinical reports. Data from clinical quantitative Ig assay. C) Percent ASCs of total BMMCs for HDs (left) and patients with NDMM, by timepoint (x-axis). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to HDs. Data from MM longitudinal BM CITEseq. *Q<0.1; **Q<0.01; ***Q<0.001 D) Percent non-malignant ASCs of total ASCs for patients with NDMM, by timepoint (x-axis). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to PRETX. Data from MM longitudinal BM CITEseq. ***Q<0.001 E) Percent non-malignant ASC subset of total BMMCs for HDs (left) and patients with NDMM, by timepoint (x-axis) and subset (panels). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to HDs. Data from MM longitudinal BM CITEseq. *Q<0.1; **Q<0.01; ***Q<0.001

Journal: bioRxiv

Article Title: Multi-omic profiling of human antibody-secreting cells reveals diverse subsets sustain durable humoral immunity

doi: 10.64898/2026.04.13.717827

Figure Lengend Snippet: A) Experimental diagram. B) Serum Ig concentrations of patients with NDMM by timepoint (x-axis), isotype (y-axis), and the isotype of each patient’s malignant cell (shapes). Transparency indicates values outside the healthy reference ranges specified in the clinical reports. Data from clinical quantitative Ig assay. C) Percent ASCs of total BMMCs for HDs (left) and patients with NDMM, by timepoint (x-axis). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to HDs. Data from MM longitudinal BM CITEseq. *Q<0.1; **Q<0.01; ***Q<0.001 D) Percent non-malignant ASCs of total ASCs for patients with NDMM, by timepoint (x-axis). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to PRETX. Data from MM longitudinal BM CITEseq. ***Q<0.001 E) Percent non-malignant ASC subset of total BMMCs for HDs (left) and patients with NDMM, by timepoint (x-axis) and subset (panels). Crossbar indicates mean. Q-values calculated by Wilcoxon rank sum test with FDR correction, comparing to HDs. Data from MM longitudinal BM CITEseq. *Q<0.1; **Q<0.01; ***Q<0.001

Article Snippet: For the ASC culture condition screen, total BM ASCs were stimulated for 72 hours with CpG ODN 2006 (10μg/mL, Invivogen) or BCR crosslinker (anti-kappa light chain; 1μg/mL, Southern Biotech) with various combinations of stimulatory reagents, including MEGACD40L (0.1μg/ml, Enzo Life Sciences), BAFF (1μg/mL, PeproTech), CXCL12 (0.1μg/ml, R&D Systems), IL-2 (0.1μg/mL, Biolegend), and IL-21 (0.1μg/mL, PeproTech).

Techniques: